PT-141 (10mg)
Rated 4.8 out of 5
$97.99
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist investigated for its potential in addressing sexual dysfunction. Unlike PDE5 inhibitors, it acts through central nervous system pathways rather than vascular mechanisms, offering a distinct pharmacological profile. Clinically, PT-141 has received approval for generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Requires reconstitution before use.
Crypto payments only for now. More payment options coming soon.In progress
- • Third-party COA verification (≥98% purity) per lot
- • Manufactured in cGMP-compliant facilities
- • Sturdy packaging and fast shipping
Research Use Only: All materials are supplied exclusively for in vitro research and laboratory work by qualified professionals and are not marketed as drugs, supplements, or medical products.
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist investigated for its potential in addressing sexual dysfunction. Unlike PDE5 inhibitors, it acts through central nervous system pathways rather than vascular mechanisms, offering a distinct pharmacological profile. Clinically, PT-141 has received approval for generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Requires reconstitution before use.
Inside Peptide Research
How researchers study peptides in the lab
Trusted by researchers
Verified quality.
COA-backed lots, careful packing, and fast dispatch.
Lot testing
3rd‑party lab
Purity
≥98% (COA)
Screening
6‑panel testing
All products are supplied exclusively for qualified research and laboratory use and are not marketed as drugs, supplements, or medical treatments.
Certificate of Analysis
Open the lab report to confirm identity, purity, and analytical results.
Product usage
This material is sold strictly for qualified laboratory and in vitro research. It is not a drug, food, dietary supplement, or cosmetic and is not approved for human or animal use. Any attempt to ingest, inject, or otherwise introduce this material into the body is prohibited. Misuse, misbranding, or reselling this material for non-research purposes is strictly forbidden. Information provided on this site is for educational purposes only. The statements made within this website have not been evaluated by the U.S. Food and Drug Administration (FDA). Neither the statements nor the products offered by this company are intended to diagnose, treat, cure, or prevent any disease.
Table of Contents
1. Characteristics
2. How does PT-141 work?
PT-141 (Bremelanotide) operates primarily as a melanocortin receptor agonist, with preferential affinity for MC4R and MC1R. Rather than acting on vascular mechanisms as PDE5 inhibitors do, its activity is centrally mediated, targeting neural circuits directly involved in sexual response.
3. Mechanism
- Central Nervous System: MC4R activation in hypothalamic and brainstem regions influences neural pathways governing sexual desire and arousal, representing a pharmacologically distinct approach to sexual health research.
- Neurotransmitter Modulation: Evidence suggests dopamine release in the medial preoptic area, a region integral to sexual motivation, is upregulated through PT-141 activity.
- Peripheral Effects: MC1R interactions with melanocytes have been investigated separately for potential implications in skin pigmentation research.
4. Research
- HSDD in Premenopausal Women: Multiple Phase III trials assessed efficacy using validated instruments including the Female Sexual Function Index (FSFI) and Female Sexual Distress Scale (FSDS-DAO), examining dosing regimens and administration variables across study populations.
- Male Sexual Function: Exploratory studies have examined effects on erectile function, though this falls outside current FDA-approved indications.
- Dermatology: Limited investigation into melanogenesis and pigmentation disorder applications has been conducted via MC1R pathway activity.
- Cardiovascular Monitoring: Blood pressure and heart rate effects have been evaluated primarily within safety assessment frameworks across clinical studies.
5. Side Effects
Nausea, flushing, and headache represent the most frequently reported adverse effects. Focal hyperpigmentation has also been observed, though this is generally reversible upon discontinuation.
6. Summary
PT-141's approval for HSDD in premenopausal women marked a meaningful milestone in female sexual health research, distinguishing itself through central rather than peripheral mechanisms of action. Active investigation continues across its pharmacological profile, long-term safety data, and potential applicability beyond its current approved indication.
7. References
- 1. Ratnasiri MDK et al. Current Drug Safety, 2022. Association between Bremelanotide and Hyponatremia. PubMed 35428435
- 2. Hadley ME, Dorr RT. Peptides, 2006. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. PubMed 14999221
- 3. Simon JA et al. Obstetrics and Gynecology, 2019. Long-Term Safety and Efficacy of Bremelanotide for HSDD. PubMed 31395204
- 4. Pfaus JG. Journal of Sexual Medicine, 2009. Pathways of sexual desire. PubMed 21303940
- 5. Safarinejad MR et al. Journal of Sexual Medicine, 2008. Efficacy and safety of bremelanotide in female subjects with arousal disorder. PubMed 23899745
8. Research use
All products on this site are intended exclusively for research and development use. Products are not for human or animal consumption of any kind.
Your Reliable Source for High-Quality Peptides
Consistent quality, clear documentation, and dependable shipping so you can run your work with confidence.
Consistent Quality
Every batch is produced to tight internal specs with purity targets of ≥98% and clear lot-level documentation for lab records.
Documented & Verified
Lots are matched to COA and analytical data so every vial can be traced back to its testing history when you need it.
Fast, Careful Shipping
Orders are packed in sturdy, lab-ready materials and shipped quickly with trusted couriers to help minimize transit-related risks.